Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.

[1]  A. Coats,et al.  Ethics in the authorship and publishing of scientific articles , 2010 .

[2]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[3]  M. Bolli,et al.  Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist , 2008, Journal of Pharmacology and Experimental Therapeutics.

[4]  F. Fedele,et al.  Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension , 2008, Regulatory Peptides.

[5]  T. Fleming,et al.  Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. , 2008, Chest.

[6]  A. Coca,et al.  Aldosterone Escape With Diuretic or Angiotensin‐Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Combination Therapy in Patients With Mild to Moderate Hypertension , 2007, Journal of clinical hypertension.

[7]  M. Humbert,et al.  Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. , 2007, Chest.

[8]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[9]  M. Humbert,et al.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.

[10]  T. Welte,et al.  Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.

[11]  R. Barst,et al.  Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[12]  F. Fedele,et al.  Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease , 2005, Regulatory Peptides.

[13]  J. Dingemanse,et al.  Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist , 2004, Clinical pharmacokinetics.

[14]  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[15]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[16]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[17]  C. Letizia,et al.  Plasma endothelin-1 levels in normotensive and borderline hypertensive subjects during a standard cold pressor test. , 1995, Journal of human hypertension.

[18]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[19]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.